Loading stock data…
Abbott Laboratories (ABT)
$93.10-1.02 (-1.08%)
Market OpenUpdated 3:10 PM EDT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Abbott Laboratories in the Healthcare sector is trading at $93.62 with a market capitalization of $151.2B. Wall Street consensus targets $116.54 (24 analysts), implying a +24.5% move over the next 12 months. The stock is currently 32% below its 52-week high of $137.49, remaining 16.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +24.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.16B↓ | $11.46B↑ | $11.37B↑ | $11.14B↑ | $10.36B |
| Gross Profit | $6.27B↓ | $6.54B↑ | $6.29B | $6.29B↑ | $5.89B |
| Operating Income | $1.34B↓ | $2.25B↑ | $2.06B↑ | $2.05B↑ | $1.69B |
| Net Income | $1.08B↓ | $1.78B↑ | $1.64B↓ | $1.78B↑ | $1.32B |
Peer Comparison
JNJUNHPFE
Fundamentals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$151.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.32
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.62%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.06%
Volume
Today's trading volume
5.90M
Recent News
Update: Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks
(Updates with DOJ's response in the fifth and sixth paragraphs.) Abbott Laboratories (ABT) will n
How Abbott's Largest Segment Is Preparing for the Next Growth Phase
ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.
Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks
Abbott Laboratories (ABT) will not face criminal charges after the US Department of Justice closed a
The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case.
Some prosecutors believed they had enough to charge Abbott Laboratories, but senior officials opted for civil settlement.
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth
Abbott Laboratories (NYSE:ABT) is among the Best Brain-Computer Interface Stocks. On June 4, Reuters reported a federal judge ruled that Abbott Laboratories (NYSE:ABT) must face a proposed class-action lawsuit alleging it misled consumers by marketing PediaSure Grow & Gain drinks as “clinically proven” to help children grow. US District Judge Paul Engelmayer said labeling featuring a […]